Core Insights - The 11th Bio-based Conference and Exhibition will be held in Shanghai from May 20-22, focusing on bio-based chemicals and materials, featuring 11 thematic forums, 7 concurrent activities, and 1000 new product displays [2] - The article outlines the basic information, main business composition, ongoing projects, and development strategies of ten leading companies in the bio-manufacturing industry, including Kasei Biotech, Huaheng Biotech, and others [2] Group 1: Kasei Biotech (688065) - Kasei Biotech achieved a revenue of 3.295 billion yuan in 2025, marking an 11.41% year-on-year increase, with a net profit of 566 million yuan, up 15.7% [3] - The main business composition includes synthetic bio-materials, with long-chain dicarboxylic acids generating 2.67 billion yuan in revenue, accounting for 90.26% of total income [6] - Ongoing projects focus on bio-manufacturing research, including the development of fermentation technology for bio-based materials and high-throughput microbial screening systems [7][8] Group 2: Huaheng Biotech (688639) - Huaheng Biotech plans to list in Hong Kong, with projected revenue of 2.885 billion yuan in 2025, a 32.5% increase, but a net profit decrease of approximately 30% [9][10] - The main business composition includes amino acids, contributing 1.509 billion yuan, and vitamins, contributing 207 million yuan, with a significant portion of revenue coming from overseas [11] - Ongoing projects include optimizing amino acid production strains and developing high-purity amino acid removal processes [12][13] Group 3: Huadong Medicine (000963) - Huadong Medicine expects a revenue of 41.906 billion yuan in 2024, a 3.16% increase, with a net profit of 3.512 billion yuan, up 23.72% [15] - The industrial microbiology segment saw revenue growth from 510 million yuan in 2022 to 711 million yuan in 2024, with a CAGR of 18.07% [15] - The company has initiated 393 research projects in the industrial microbiology field, focusing on xRNA materials and health-related products [19] Group 4: Meihua Biotech (600873) - Meihua Biotech reported a revenue of 25.069 billion yuan in 2024, a 9.69% decrease, with a net profit of 2.740 billion yuan, down 13.85% [28] - The company focuses on amino acid production and has developed a comprehensive ecosystem including animal nutrition and pharmaceutical-grade amino acids [27] - Research and development investments reached 733 million yuan in 2024, emphasizing the development of new technologies and strains [31] Group 5: Chuan Ning Biotech (301301) - Chuan Ning Biotech achieved a revenue of 5.758 billion yuan in 2024, a 19.38% increase, with a net profit of 1.400 billion yuan, up 48.88% [36] - The main business composition is primarily in pharmaceutical manufacturing, with a significant portion of revenue from pharmaceutical intermediates [38] - The company has established a commercial system integrating product selection, research, and large-scale production [37]

Core Viewpoint - Garden Biologics has shown fluctuations in financing activities and stock performance, with a notable decrease in net profit and revenue in recent financial reports [1][2]. Financing Activities - On February 25, Garden Biologics experienced a financing buy-in of 37.78 million yuan, while the financing repayment amounted to 57.76 million yuan, resulting in a net financing outflow of 19.98 million yuan [1]. - The total financing and margin trading balance for Garden Biologics reached 789 million yuan, with the financing balance accounting for 8.47% of the circulating market value, indicating a high level compared to the past year [1]. - In terms of securities lending, 500 shares were repaid, and 800 shares were sold on February 25, with a selling amount of 13,700 yuan, while the securities lending balance was 2.31 million yuan, also at a high level compared to the past year [1]. Company Overview - Zhejiang Garden Biologics Co., Ltd. was established on December 18, 2000, and went public on October 9, 2014. The company focuses on developing, producing, and selling products related to a complete vitamin D3 industry chain [1]. - The main revenue sources for the company include vitamin products (47.41%), pharmaceuticals (30.22%), lanolin and its derivatives (20.93%), and other minor categories [1]. Shareholder Information - As of February 10, the number of shareholders for Garden Biologics increased by 2.92% to 24,300, while the average circulating shares per person decreased by 2.84% to 22,025 shares [2]. - Cumulatively, the company has distributed 446 million yuan in dividends since its A-share listing, with 178 million yuan distributed over the past three years [3]. - Among the top ten circulating shareholders, the Southern CSI 1000 ETF holds 3.48 million shares, a decrease of 48,400 shares from the previous period [3].

Group 1 - Garden Biologics' stock increased by 5.06%, reaching 18.68 CNY per share, with a trading volume of 356 million CNY and a turnover rate of 3.65%, resulting in a total market capitalization of 10.152 billion CNY [1] - The company, Zhejiang Garden Biologics Co., Ltd., was established on December 18, 2000, and went public on October 9, 2014. Its main business focuses on developing, producing, and selling products related to a complete vitamin D3 industry chain [1] - The revenue composition of the company includes vitamin products at 47.41%, pharmaceuticals at 30.22%, lanolin and its derivatives at 20.93%, sales of raw materials and others at 1.01%, rental income at 0.31%, other trade products at 0.10%, and medical devices at 0.01% [1] Group 2 - Southern Fund's Southern CSI 1000 ETF (512100) is among the top ten circulating shareholders of Garden Biologics, having reduced its holdings by 48,400 shares to 3.4785 million shares, representing 0.65% of the circulating shares [2] - The Southern CSI 1000 ETF (512100) was established on September 29, 2016, with a latest scale of 78.996 billion CNY. Year-to-date returns are 8.61%, ranking 1564 out of 5569 in its category, while the one-year return is 34.61%, ranking 1862 out of 4295 [2] Group 3 - The fund manager of Southern CSI 1000 ETF (512100) is Cui Lei, who has been in the position for 7 years and 98 days. The total asset scale under management is 137.02 billion CNY, with the best fund return during the tenure being 251.88% and the worst being -15.93% [3]

Group 1 - Garden Biologics' stock increased by 5.42%, reaching 19.05 CNY per share, with a trading volume of 245 million CNY and a turnover rate of 2.47%, resulting in a total market capitalization of 10.353 billion CNY [1] - The company, Zhejiang Garden Biologics Co., Ltd., was established on December 18, 2000, and went public on October 9, 2014. Its main business focuses on developing, producing, and selling products related to a complete vitamin D3 industry chain [1] - The revenue composition of the company includes vitamin products at 47.41%, pharmaceuticals at 30.22%, lanolin and its derivatives at 20.93%, sales of raw materials and others at 1.01%, rental income at 0.31%, other trade products at 0.10%, and medical devices at 0.01% [1] Group 2 - Among the top circulating shareholders of Garden Biologics, a fund under Southern Fund holds a position. The Southern CSI 1000 ETF (512100) reduced its holdings by 48,400 shares in the third quarter, now holding 3.4785 million shares, which is 0.65% of the circulating shares [2] - The Southern CSI 1000 ETF (512100) was established on September 29, 2016, with a latest scale of 78.996 billion CNY. Year-to-date returns are 6.21%, ranking 1574 out of 5564 in its category; the one-year return is 39%, ranking 1777 out of 4288; and since inception, the return is 21.47% [2] - The fund manager of Southern CSI 1000 ETF (512100) is Cui Lei, who has been in the position for 7 years and 93 days, managing total assets of 137.02 billion CNY. The best fund return during this period is 279.97%, while the worst is -15.93% [2]

Core Viewpoint - The company anticipates stable growth in its business operations, with a reported revenue increase of 14% year-on-year for the first three quarters of 2025, amounting to RMB 12.93 billion [1] Financial Performance - The company's revenue for the first three quarters of 2025 reached RMB 12.93 billion, reflecting a 14% year-on-year growth [1] - Gross profit increased by 4% to RMB 3.6 billion, driven by the rising penetration of liquid amino acids and double-digit sales growth in specialty products [1] Market Dynamics - The market demand is expected to remain strong; however, the entry of new methionine and vitamin production capacity into the market is intensifying industry competition [1] - The company is committed to supporting business growth and will continue to invest for future expansion [1] Communication and Disclosure - The company emphasizes adherence to information disclosure regulations, ensuring that all significant information is released through designated channels in a timely and accurate manner [1] - Investors are encouraged to monitor company announcements and periodic reports for authoritative operational data [1]

Core Viewpoint - The company held its first extraordinary board meeting of 2026, where several key resolutions were passed, including the approval of bank credit limits and related party transactions for the year [1][2][4][6][10]. Group 1: Bank Credit and Financing - The board approved a total bank credit limit of 5.771 billion yuan for 2026, with 1.960 billion yuan allocated to the headquarters and 3.811 billion yuan to subsidiaries [2]. - Additionally, the company and its subsidiaries will apply for project financing credit totaling 1.145 billion yuan, with 740 million yuan for the headquarters and 405 million yuan for subsidiaries [2]. Group 2: Related Party Transactions - The board approved ongoing sales of poultry vaccines and veterinary medicines to Shandong Zhongxin Food Group Co., Ltd., with an estimated transaction amount not exceeding 24 million yuan for 2026 [4][14]. - The company will also continue to purchase production raw materials from Xiamen Jindawei Group Co., Ltd., with an estimated transaction amount not exceeding 31 million yuan for 2026 [6][16]. Group 3: Internal Audit and Salary Budget - The board approved the internal audit plan for 2026 [8][9]. - The board also approved the salary budget for 2025, along with the evaluation report for the total salary for 2024 [10][11]. Group 4: Upcoming Shareholder Meeting - The board agreed to convene the second extraordinary shareholder meeting of 2026 to discuss additional matters requiring shareholder approval [11]. Group 5: Performance Forecast - The company anticipates a net profit attributable to shareholders of 148.59 million to 192.29 million yuan for 2025, representing an increase of 77.70 million to 121.41 million yuan compared to the previous year, which is a year-on-year increase of 109.62% to 171.27% [32][33]. - However, the net profit after deducting non-recurring gains and losses is expected to be between 16.90 million and 23.24 million yuan, a decrease of 38.90 million to 45.24 million yuan compared to the previous year, reflecting a year-on-year decrease of 62.60% to 72.80% [33]. Group 6: Reasons for Performance Increase - The increase in net profit is attributed to gains from investments, including the subscription of convertible bonds issued by Xiamen Jindawei Group and the abandonment of the right of first refusal for shares in Zhongpu Biopharmaceutical Co., Ltd. [37]. - The company has also optimized its marketing structure and product development to enhance operational efficiency [37].

Group 1 - Garden Biologics experienced a stock price increase of 3.57% on January 15, with a trading volume of 828 million yuan [1] - The company had a net financing buy of -2.61 million yuan on the same day, with a total financing and margin balance of 732 million yuan [1] - The financing balance of Garden Biologics is 730 million yuan, accounting for 8.13% of its circulating market value, which is above the 80th percentile level over the past year [1] Group 2 - As of December 31, the number of shareholders for Garden Biologics was 26,200, a decrease of 12.35% from the previous period [2] - For the period from January to September 2025, the company reported a revenue of 936 million yuan, a year-on-year decrease of 0.20%, and a net profit attributable to shareholders of 234 million yuan, down 3.07% year-on-year [2] - The company has distributed a total of 446 million yuan in dividends since its A-share listing, with 178 million yuan distributed in the last three years [2]

Group 1 - Garden Biologics experienced a stock decline of 0.90% on January 9, with a trading volume of 484 million yuan [1] - The company had a net financing purchase of 22.48 million yuan on the same day, with a total financing balance of 683 million yuan, accounting for 7.62% of its market capitalization [1] - The company’s financing balance is above the 60th percentile of the past year, indicating a high level of financing activity [1] Group 2 - As of December 31, the number of shareholders for Garden Biologics decreased by 12.35% to 26,200, while the average circulating shares per person increased by 14.09% to 20,383 shares [2] - For the period from January to September 2025, the company reported a revenue of 936 million yuan, a slight decrease of 0.20% year-on-year, and a net profit of 234 million yuan, down 3.07% year-on-year [2] - The company has distributed a total of 446 million yuan in dividends since its A-share listing, with 178 million yuan distributed in the last three years [2]

Core Viewpoint - Garden Biologics has seen a stock price increase of 5.04% on January 8, reaching 16.67 CNY per share, with a trading volume of 648 million CNY and a turnover rate of 7.39%, resulting in a total market capitalization of 9.06 billion CNY [1] Group 1: Company Overview - Zhejiang Garden Biologics Co., Ltd. was established on December 18, 2000, and went public on October 9, 2014 [1] - The company's main business focuses on developing, producing, and selling products related to a complete vitamin D3 industry chain [1] - Revenue composition includes: Vitamin products 47.41%, Pharmaceuticals 30.22%, Lanolin and derivatives 20.93%, Sales of raw materials and others 1.01%, Rental income 0.31%, Other trade products 0.10%, Medical devices 0.01% [1] Group 2: Shareholder Information - Southern Fund's Southern CSI 1000 ETF (512100) is among the top ten circulating shareholders of Garden Biologics, having reduced its holdings by 48,400 shares in the third quarter, now holding 3.4785 million shares, which is 0.65% of the circulating shares [2] - The ETF has generated an estimated floating profit of approximately 2.7828 million CNY today and 2.6089 million CNY during the three-day stock price increase [2] Group 3: Fund Manager Profile - The fund manager of Southern CSI 1000 ETF (512100) is Cui Lei, who has been in the position for 7 years and 64 days [3] - The total asset size of the fund is 122.76 billion CNY, with the best fund return during the tenure being 208.53% and the worst being -15.93% [3]

Core Insights - Garden Biologics experienced a decline of 2.73% in stock price on November 20, with a trading volume of 164 million yuan [1] - The company reported a financing buy-in amount of 24.2 million yuan and a net financing buy of 1.3 million yuan on the same day [1][2] - As of November 20, the total financing and securities lending balance for Garden Biologics was 548 million yuan, with a financing balance of 547 million yuan, representing 7.26% of the circulating market value [1] Financing and Securities Lending - On November 20, the financing buy-in for Garden Biologics was 24.2 million yuan, with a financing balance of 547 million yuan, which is below the 10% percentile level over the past year [1] - The company repaid 6,900 shares in securities lending and sold 29,300 shares, with a selling amount of 406,400 yuan [1] - The securities lending balance was 773,900 yuan, which is above the 60% percentile level over the past year, indicating a relatively high position [1] Company Overview - Garden Biologics, established on December 18, 2000, and listed on October 9, 2014, is located in Jinhua City, Zhejiang Province [1] - The company's main business focuses on developing, producing, and selling products related to a complete vitamin D3 industry chain [1] - The revenue composition includes vitamin products (47.41%), pharmaceuticals (30.22%), lanolin and derivatives (20.93%), and other minor segments [1] Financial Performance - For the period from January to September 2025, Garden Biologics reported a revenue of 936 million yuan, a slight decrease of 0.20% year-on-year [2] - The net profit attributable to the parent company was 234 million yuan, reflecting a year-on-year decrease of 3.07% [2] Shareholder Information - As of November 10, the number of shareholders for Garden Biologics was 29,100, an increase of 2.11% from the previous period [2] - The average circulating shares per person decreased by 2.06% to 18,378 shares [2] - Cumulatively, the company has distributed 446 million yuan in dividends since its A-share listing, with 178 million yuan distributed over the past three years [3]